Suzhou Xueji Biotechnology

The company's core business revolves around its advanced platform for stem cell reprogramming, gene editing, and directed differentiation technologies. This enables the large-scale, stable, and safe production of blood cells outside the body, aiming to reduce the reliance on blood donations for transfusions. Its primary market includes healthcare providers and patients dealing with hematological diseases, cancer, liver disease, and critical illnesses that result in platelet deficiencies. The business model is centered on the research, development, and eventual commercialization of these cell-based therapies and related drugs.

HemaCell's lead product candidate is an injectable platelet solution derived from stem cells, designed to treat thrombocytopenia (platelet deficiency). This product addresses the significant clinical shortage of platelets, which are crucial for blood clotting and are often required by patients undergoing chemotherapy or suffering from various diseases. The company is also developing innovative drugs to manage other platelet-related disorders, including thrombosis. A key achievement is securing Orphan Drug Designation (ODD) from the U.S. FDA for its platelet injection XJ-PLT-001, highlighting its potential in treating rare conditions.

Since its inception, the company has successfully secured multiple rounds of funding. It completed its third financing round, a Pre-Series A+, in May 2022, attracting investment from notable venture capital firms such as Northern Light Venture Capital, Country Garden Ventures, and Founder Hesheng. This financial backing supports the ongoing clinical trials and development of its drug pipeline.